2023 World Conference on Lung Cancer (Posters)-P2.27. Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins

P2.27. Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins - PDF(Slides)

Pdf Summary

The study aimed to understand the perceptions of patients with advanced/metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) regarding the benefits and risks of EGFR targeted therapies. Amivantamab and mobocertinib are two novel EGFR targeted therapies that have been approved for use in this patient population. The study involved qualitative interviews with 15 patients to explore their preferences and experiences. Participants reported symptoms such as cough, fatigue, shortness of breath, and pain before their diagnosis, which significantly impacted their quality of life. When it comes to treatment benefits, participants perceived treatment as effective when they experienced symptom relief, tumor regression, improved walking ability, and enhanced quality of life. Overall survival was ranked as the most meaningful measure of treatment efficacy, followed by overall response rate and disease control rate. Participants also expressed a desire to know the probability of tumor shrinkage or stability with treatment. The most frequently experienced adverse events were fatigue, nausea and vomiting, rash, diarrhea, and infusion-related reactions. Participants considered heart problems, interstitial lung disease, and severe nausea and vomiting as the three most important adverse events to avoid. Participants expressed concerns about the lack of available treatments for managing heart problems and interstitial lung disease. They felt a sense of control over adverse events such as diarrhea, nausea and vomiting, and rash as these could be managed with medications. The study highlights the importance of understanding patient preferences and perceptions to inform treatment discussions and decision-making in advanced/metastatic NSCLC with EGFRex20ins. Further studies should investigate whether patients with NSCLC would be willing to trade adverse events for treatment efficacy.

Asset Subtitle

Jun Zhang

Meta Tag

Speaker Jun Zhang

Topic Patient Advocacy

Keywords

NSCLC

EGFR

ex20ins

EGFR targeted therapies

symptom relief

tumor regression

overall survival

adverse events

fatigue

heart problems